Americans pay 300% more for this prostate cancer drug than much of the rest of the world

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 29 March, 2016 by The TZ Newswire Staff

Americans pay 300% more for this prostate cancer drug than much of the rest of the world

Nonprofits and now 12 congresspeople are petitioning the government to use a rarely-used right to revoke patents in the case of a prostate cancer drug.
read more

See also
- Next Article The Wall Street Journal: Warming ocean is killing Great Barrier Reef’s once-colorful coral
- Previous Article Tesla Motors, Inc. Reports Deliveries Next Week: Will It Beat Its Guidance?
Editorial Calender

March 2016

M T W T F S S

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

« Feb Apr »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 29 March, 2016 by The TZ Newswire Staff

Americans pay 300% more for this prostate cancer drug than much of the rest of the world

See also

Editorial Calender

Recent Tags